Skip to main content
Premium Trial:

Request an Annual Quote

Sera Prognostics PreTRM Test

Sera Prognostics has announced a program for limited commercial access to PreTRM, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman's risk of preterm birth. The test will be made available in limited locations in the US, beginning with selected clinical sites that participated in the Proteomic Assessment of Preterm Risk study. All testing will be conducted at Sera's CLIA-certified laboratory in response to orders from women's healthcare professionals. Following the early access outreach to physicians in selected markets this fall, Sera is planning for a wider national PreTRM rollout in 2016, the company said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more